Email bulletin archive Archive November 2022 News from the AASLD Liver Meeting, Washington, DC Only 11 countries on target to eliminate hepatitis C by 2030 Simplified tenofovir regimen as effective as recommended preventive treatment in pregnant women with hepatitis B Some people remain at risk for liver cancer after being cured of hepatitis C UK community test-and-treat service achieves high hepatitis C cure rate in people who use drugs Severe acute hepatitis in children still does not have a definitive cause Bepirovirsen treatment leads to sustained loss of hepatitis B markers for up to one in five VIR-2218 combined with monoclonal antibody or pegylated interferon delivers potent suppression of hepatitis B July 2022 News from the 2022 International Liver Congress People cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes WHO publishes updated guidance on hepatitis C infection Bulevirtide leads to sustained improvement for people with hepatitis D Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies Short-course treatment prevents hepatitis C after organ transplant Re-treatment of hepatitis C is highly effective after the first combination fails Is this your copy of the infohep news bulletin? May 2022 Severe acute hepatitis of unknown cause in children: an update UK emergency department screening for viral hepatitis feasible and acceptable Ukraine: viral hepatitis and harm reduction services for refugees People with diabetes or heavy alcohol consumption at higher risk of severe fibrosis after hepatitis C cure Is this your copy of the infohep news bulletin? April 2022 Severe acute hepatitis of unknown origin in children Sofosbuvir/velpatasvir is suitable for treatment of genotype 4 variants in Africa UK report urges re-think on hepatitis C reinfection High hepatitis C reinfection rate in prison study highlights harm reduction needs Test-and-treat leads to sustained fall in hepatitis C in Swiss gay men with HIV Is this your copy of the infohep news bulletin? March 2022 COVID-19 pandemic led to a 30% drop in new hepatitis C treatments in the United States Accessible care achieves higher hepatitis C cure rate in people who inject drugs Depression, anxiety, cognitive performance improve after hepatitis C cure Hepatitis C prevalence down by 40% since 2015 in England Metabolic disorders cause liver damage in people with HIV more often than viral hepatitis in lower-income countries Fatty liver disease raises the risk of cardiovascular disease in people with HIV Is this your copy of the infohep news bulletin? February 2022 Immunoglobulin-free strategy highly effective for prevention of mother-to-child hepatitis B transmission in Cambodia Universal hepatitis C screening in pregnancy improves case detection Antihistamine use halved the risk of liver cancer in people with viral hepatitis Hepatitis C treatment and cure targets for people living with HIV still not being met in Europe New cases of hepatitis C declining in people with HIV as access to treatment broadens Is this your copy of the infohep news bulletin? January 2022 Some people remain at risk for liver cancer despite hepatitis C treatment Bulevirtide for hepatitis D proves effective in real-world studies Hepatitis B may increase cancer risk in people with HIV One in five new cases of hepatitis C in people who inject drugs due to unstable housing, modelling shows Re-infection with hepatitis C has fallen among people with HIV in Europe Prioritise harm reduction services to prevent hepatitis C re-infection, Scottish study finds Is this your copy of the infohep news bulletin? 2022202120202019201820172016201520142013 Other pages in this section Latest news All the news Conference news Email bulletin archive